DNDi - NewsLetter


HOME
ABOUT DNDi EDITORIAL: "Key Challenges for Successful Partnerships" CALENDAR HOW YOU CAN HELP DNDi?
DNDi's Malaria Project: A Model for Innovative Partnerships? Fighting Malaria in the Legal Amazon, Brazil ASMQ in a Nutshell ASAQ: a new Business Model for a "Big Pharma" ASMQ: a Great Public-Private, Intercontinental Partnership Why Lead Platforms are Crucial to Boost Innovation for Neglected Diseases Asian Region Makes Use of its Biodiversity to Identify New Bioactive Molecules Our moral responsibility to address Public Health Issues Four Characteristics For Partnership Paving the Way to Win-Win Partnerships DNDi R&D Projects-2008 Outlook Synergise Efforts with Anacor, GSK, IRD, Eskitis, UNC, and Intitut Pasteur Korea. Operational Challenges: Clinical Trial Partnerships in Africa LEAP: 4 Years and Going Strong... Concentrated HAT Platform Efforts in the 5 Most Affected Countries Advances at the DNDi Regional Support Office KEMRI, Nairobi Actions to Increase Awareness and Visibility in the Asian Region DNDi's Launch of ASMQ in Rio de Janeiro DNDi Project Collaboration in Japan DNDi in DRC brings Regular Support to the Clinical Trials From Discovery to Clinical Trials in India DNDi Strengthens North American Presence DNDi Joins Scientists Without Borders^SM Fexinidazole: A Rediscovered Compound Progresses as a Preclinical Drug Candidate for HAT Neglected by Everybody: PLoS NTD Publishes Media Analysis on Neglected Diseases DNDi Participates at International Meeting on Chagas Disease DNDi Awarded by the French Societé de Pathologie Exotique DNDi Receives Goodwin Award for Its Social Entrepeneurial Approach for the Most Neglected Diversifying Sources of Funding News from Donors IGWG: An Important Step Towards Boosting Innovation Contact DNDi

LEAP: 4 Years and Going Strong...

Some of the LEAP Platform's Accomplishments To-date Include:

Assessment of regional capacity in R&D for neglected diseases
Development of the LEAP 0104 Paromomycin multi-centre clinical trial comparing Paromomycin, Sodium Stibogluconate (SSG), and a combination of Paromomycin and SSG for treatment of VL
Two clinical trial sites established in Ethiopia, 2 in Sudan, 1 in Kenya and 1 future site in Uganda
Training of clinical monitors, Data and Safety Monitoring Board (DSMB) members and investigators in good clinical practice (GCP)
Regular communications network established with a newsletter and biannual meetings
Clinical trial capacity strengthening in Ethiopia, Kenya, Sudan, and Uganda
Building and opening the leishmaniasis Research and Treatment Centre in Arba Minch, and Gondar, Ethiopia
Treatment centre/laboratory training under construction, planned for Dooka (opening in 2008)
Capacity strengthening of parasite classification research through technology transfer and training
Development and roll-out of national VL treatment guidelines in Ethiopia.

Published by Drugs for Neglected Diseases Initiative - 15 Chemin Louis-Dunant 1202 Geneva Switzerland - Photo credits: DNDi unless otherwise stated - Editor: Sadia Kaenzig - Tel: +41 22 906 9230 - Fax: +41 22 906 9231 - www.dndi.org